MedWatch

Japanese approval boosts Novo’s fight for market shares

According to Sydbank, the rapid approval of Novo Nordisk’s new insulin in Japan could have a positive effect on the company’s decline in market shares. Moreover, it sends an important signal to the rest of the world.

Foto: Colourbox

Novo Nordisks Japanese market share will hopefully benefit from the fast approval of the company’s new insulin Tresiba, says Sydbank, after an expert committee recommended Japanese health authorities to approve the drug last week.

“We assess that the setbacks in Japan are primarily the result of an increased migration among diabetics in Japan from premix insulin (a mix of long-acting insulin and fast-acting insulin), where Novo is very well positioned, to the long-acting insulins – especially to the rival drug Lantus. We thus see an approval of Tresiba as essential to Novo Nordisk in the battle to reconquer market shares on the Japnase insulin market,” writes Sydbank analyst Søren Løntoft in his analysis of the company.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier